Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

232 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Myeloproliferative disorders in pregnancy.
Harrison CN, Robinson SE. Harrison CN, et al. Hematol Oncol Clin North Am. 2011 Apr;25(2):261-75, vii. doi: 10.1016/j.hoc.2011.01.008. Hematol Oncol Clin North Am. 2011. PMID: 21444029 Review.
Molecular diagnosis of the myeloproliferative neoplasms: UK guidelines for the detection of JAK2 V617F and other relevant mutations.
Bench AJ, White HE, Foroni L, Godfrey AL, Gerrard G, Akiki S, Awan A, Carter I, Goday-Fernandez A, Langabeer SE, Clench T, Clark J, Evans PA, Grimwade D, Schuh A, McMullin MF, Green AR, Harrison CN, Cross NC; British Committee for Standards in Haematology. Bench AJ, et al. Among authors: harrison cn. Br J Haematol. 2013 Jan;160(1):25-34. doi: 10.1111/bjh.12075. Epub 2012 Oct 11. Br J Haematol. 2013. PMID: 23057517 Free article.
Increasing therapeutic efficacy in MPN.
Harrison CN. Harrison CN. Blood. 2014 Mar 27;123(13):1982-3. doi: 10.1182/blood-2014-02-554766. Blood. 2014. PMID: 24677402 Free article.
Clinical end points for drug treatment trials in BCR-ABL1-negative classic myeloproliferative neoplasms: consensus statements from European LeukemiaNET (ELN) and Internation Working Group-Myeloproliferative Neoplasms Research and Treatment (IWG-MRT).
Barosi G, Tefferi A, Besses C, Birgegard G, Cervantes F, Finazzi G, Gisslinger H, Griesshammer M, Harrison C, Hehlmann R, Hermouet S, Kiladjian JJ, Kröger N, Mesa R, Mc Mullin MF, Pardanani A, Passamonti F, Samuelsson J, Vannucchi AM, Reiter A, Silver RT, Verstovsek S, Tognoni G, Barbui T. Barosi G, et al. Leukemia. 2015 Jan;29(1):20-6. doi: 10.1038/leu.2014.250. Epub 2014 Aug 25. Leukemia. 2015. PMID: 25151955 Free PMC article. Review.
Update in the myeloproliferative neoplasms.
Harrison CN, McMullin MF. Harrison CN, et al. Clin Med (Lond). 2014 Dec;14 Suppl 6:s66-70. doi: 10.7861/clinmedicine.14-6-s66. Clin Med (Lond). 2014. PMID: 25468923 Free article.
Effect of mutation order on myeloproliferative neoplasms.
Ortmann CA, Kent DG, Nangalia J, Silber Y, Wedge DC, Grinfeld J, Baxter EJ, Massie CE, Papaemmanuil E, Menon S, Godfrey AL, Dimitropoulou D, Guglielmelli P, Bellosillo B, Besses C, Döhner K, Harrison CN, Vassiliou GS, Vannucchi A, Campbell PJ, Green AR. Ortmann CA, et al. Among authors: harrison cn. N Engl J Med. 2015 Feb 12;372(7):601-612. doi: 10.1056/NEJMoa1412098. N Engl J Med. 2015. PMID: 25671252 Free PMC article.
Management of MPN beyond JAK2.
Harrison CN, Garcia NC. Harrison CN, et al. Hematology Am Soc Hematol Educ Program. 2014 Dec 5;2014(1):348-54. doi: 10.1182/asheducation-2014.1.348. Epub 2014 Nov 18. Hematology Am Soc Hematol Educ Program. 2014. PMID: 25696878 Review.
232 results